Psoriatic Arthritis News

CLEVELAND — Christopher Ritchlin, MD, MPH, professor of medicine at the University of Rochester Medical Center, reviewed treatments for psoriatic arthritis, spondyloarthritis and other spondyloarthropathies at the Primary Vasculitides Pre-symposium of the Biologic Therapies VII Summit.

Patients with nail psoriasis who were treated with Xeljanz experienced improvement at week 16, compared with placebo, and improvements maintained through week 52, according to study results recently published in the Journal of the American Academy of Dermatology.

Investigators of this cross-sectional study found psoriasis and psoriatic arthritis correlated with pathologic fractures and other bone-related conditions.

There was minimal to no transfer of Cimzia from nursing mothers to breast milk, considered to be an acceptable range for breast-feeding, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

The European Commission has approved Amgevita, a biosimilar to adalimumab, for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, severe active ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis in addition to moderate to severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, non-infectious intermediate, posterior and panuveitis, moderate to severe Crohn’s disease and moderate to severe ulcerative colitis. It is also approved for Crohn’s disease in children aged 6 years and older, severe chronic plaque psoriasis in children aged 4 years and older, enthesitis-related arthritis in children aged 6 years and older and polyarticular juvenile idiopathic arthritis in children aged 2 years and older.

Cosentyx may modify the course of moderate-to-severe psoriasis, which could lead to long-term, treatment-free skin clearance, according to data presented at Maui Derm for Dermatologists in Maui, Hawaii.

Many patients with moderate-to-severe psoriasis retreated with Consentyx regained previous levels of efficacy after 16 weeks following a relapse during a treatment pause, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Misalignment in patient- and physician-reported satisfaction with disease control was associated with an increased risk for disease activity in patients with psoriatic arthritis, according to recently published data.

A phase 3 study met its primary endpoint of demonstrating that Sandoz’s GP2017, a proposed biosimilar adalimumab, has equivalent efficacy to Humira in treating moderate-to-severe chronic plaque psoriasis, according to results presented at the American Academy of Dermatology Annual Meeting in Orlando, Fla.

ORLANDO, Fla. — Patients treated with Cimzia reported statistically significant improvement in moderate-to-severe plaque psoriasis at 16 weeks, according to research presented at a late-breaking research forum of the American Academy of Dermatology meeting.